CN118243930A - Kit for monitoring diabetic nephropathy disease course and application thereof - Google Patents
Kit for monitoring diabetic nephropathy disease course and application thereof Download PDFInfo
- Publication number
- CN118243930A CN118243930A CN202211664448.4A CN202211664448A CN118243930A CN 118243930 A CN118243930 A CN 118243930A CN 202211664448 A CN202211664448 A CN 202211664448A CN 118243930 A CN118243930 A CN 118243930A
- Authority
- CN
- China
- Prior art keywords
- diabetic nephropathy
- kit
- ighg2
- serpina1
- myo5a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 33
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 33
- 238000012544 monitoring process Methods 0.000 title claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 24
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims abstract description 21
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims abstract description 21
- 101000961146 Homo sapiens Immunoglobulin heavy constant gamma 2 Proteins 0.000 claims abstract description 21
- 102100039346 Immunoglobulin heavy constant gamma 2 Human genes 0.000 claims abstract description 21
- 101000583031 Homo sapiens Unconventional myosin-Va Proteins 0.000 claims abstract description 19
- 102100030409 Unconventional myosin-Va Human genes 0.000 claims abstract description 19
- 239000000090 biomarker Substances 0.000 claims abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 210000002700 urine Anatomy 0.000 claims description 24
- 238000001514 detection method Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 101100403745 Mus musculus Myot gene Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 22
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to a kit for monitoring the disease course of diabetic nephropathy and application thereof. The kit comprises reagents for detecting the expression levels of biomarkers IGHG2, SERPINA1 and/or MYO5A in a sample. The invention utilizes IGHG2, SERPINA1 and MYO5A as the accompanying diagnostic markers of the disease course of diabetic nephropathy, and is used for indicating the disease course of the diabetic nephropathy.
Description
Technical Field
The application belongs to the field of biological diagnostic reagents, and particularly relates to a kit for monitoring the disease course of diabetic nephropathy and application thereof.
Background
Diabetes is one of the most common chronic diseases worldwide, with a number of complications. Among them, diabetic nephropathy is one of the most common microvascular complications, and has become a main cause of end-stage renal disease, which seriously threatens the life health of patients. Therefore, early diagnosis of diabetic nephropathy is critical for early intervention of the disease, reducing the occurrence and slowing down the progression of end-point nephropathy. Parameters currently used clinically to assess the extent of diabetic kidney damage are very limited, such as detection of glomerular filtration rate, urinary albumin excretion rate, and the like. However, multiple factors such as body inflammation affect these changes in the index, and clinically, this may lead to false positives. Therefore, development of biomarkers for diabetic nephropathy for clinical diagnosis has important clinical application value.
Urine is produced by kidneys, contains abundant proteins and metabolites, and can reflect various physiological and pathological information of human bodies. The urine sample has the advantages of easy acquisition, noninvasive sampling, high safety, high repeatability and the like, and is a disease detection sample widely applied in clinic. Detection of urine proteins has been used for a variety of diseases such as diabetes, inflammation, and the like.
In view of the fact that urine can directly reflect kidney health, finding new biomarkers from urine to assess the progression of diabetic nephropathy is a clinically very promising study.
Disclosure of Invention
Technical purpose
The technical aim of the invention is to provide a kit for monitoring the disease course of diabetic nephropathy, which is used for detecting the expression level of IGHG2, SERPINA1 and/or MYO5A in urine, can monitor the diabetic nephropathy with high sensitivity, and is used for indicating the disease course of the diabetic nephropathy.
Technical proposal
In one aspect, the invention provides a kit for monitoring the course of diabetic nephropathy comprising reagents for detecting the expression levels of biomarkers IGHG2, SERPINA1 and/or MYO5A in a sample.
In specific embodiments, the sample is urine.
In particular embodiments, the agent is a specific antibody directed against IGHG2, SERPINA1, and MYO5A, respectively.
In specific embodiments, the kit further comprises instructions for use.
In a specific embodiment, the application instructions of the kit describe the application method of the kit in detail, including introducing the application frequency of the kit, comparing the content change of any one of the three proteins in urine of a patient along with the increase of the patient suffering time, monitoring the trend of the protein expression quantity along with the change of the disease course time, drawing a correlation linear curve, and when the content of the protein shows a gradually-increasing linear trend along with the increase of the patient suffering time (the linear correlation is > 0.5), indicating that the diabetic nephropathy is gradually worsened, otherwise, indicating that the diabetic nephropathy is stable.
The specific antibodies of IGHG2, SERPINA1 and/or MYO5A are used for detection, and the content of the three proteins in urine of patients in different periods is compared, so that when the protein content of any one protein is increased along with the increase of the disease time of the patients, the diabetic nephropathy is gradually worsened.
In another aspect, the invention provides the use of an agent for detecting the expression level of a biomarker in the manufacture of a product for monitoring the course of diabetic nephropathy, wherein the biomarker may be one or more selected from IGHG2, SERPINA1 and MYO 5A.
In particular embodiments, the product is a detection kit.
In specific embodiments, the detection kit further comprises instructions for use of the kit.
The application carries out systematic analysis on urine proteins of large-scale (144 cases) diabetic nephropathy patients with different disease degrees, and screens proteins for indicating occurrence and development of the diabetic nephropathy by utilizing an algorithm for calculating the significance of statistical differences. As a result, IGHG2, SERPINA1 and MYO5A are found to be significantly and closely related to the progress of diabetic nephropathy, and are significantly increased along with the increase of albumin in urine of patients, so that the kit can be used as a concomitant diagnostic marker for indicating the disease progress of diabetic nephropathy.
Advantageous effects
The experimental data prove that IGHG2, SERPINA1 and MYO5A are positively correlated with the amount of Albumin (ALB) in urine of a diabetic nephropathy patient, are obviously and closely correlated with the progress of the diabetic nephropathy, are obviously increased along with the increase of albumin in urine of the patient, can be used as accompanying diagnostic markers, and can be used for indicating the disease progress of the diabetic nephropathy.
Drawings
FIG. 1 correlation of the expression level of IGHG2 (A), SERPINA1 (B) and MYO5A (C) with ALB protein in urine of diabetic patients.
FIG. 2 shows that the expression levels of IGHG2, SERPINA1 and MYO5A in urine of diabetic patients show significant differences in different degrees of disease.
Detailed Description
See fig. 1: quantitative proteomics technology based on mass spectrum is utilized to quantitatively detect urine proteins of large-scale (144 cases) clinical diabetic nephropathy patients (men, clinical patients with age above 50 years) in clinical diabetes of different disease degrees, the abundance values of three proteins IGHG2, SERPINA1 and MYO5A in urine given quantitatively based on mass spectrum are subjected to correlation analysis with the abundance values of ALB proteins (marker proteins identified by the diabetic nephropathy used clinically) obtained quantitatively based on mass spectrum, and an excel table is utilized to draw correlation curves of the three proteins IGHG2, SERPINA1 and MYO5A and ALB respectively, and corresponding linear correlation coefficients are calculated. The result shows that the expression quantity of the three proteins and the expression quantity of ALB show high positive correlation, and the correlation coefficient R 2 is higher than 0.7, which suggests that the three proteins are closely related to the worsening progress of the disease and can be used as marker proteins for detecting the disease progress.
See fig. 2: further using R language in combination with statistical analysis, the quantitative abundance values (intensity) of the mass spectra of the three proteins IGHG2, SERPINA1 and MYO5A in the urine of the normal group (HC, 44) and the different stages of diabetic nephropathy group (normal albuminuria group DM1, 74; microalbuminuria group DM2, 36; macroalbuminuria group DM3, 15) were compared, and as a result, it was found that the expression level of the three proteins IGHG2, SERPINA1 and MYO5A was increased at each stage of the disease process (DM 1 vs HC, DM2 vs DM1, DM3 vs DM 2) and a significant difference was exhibited (p < 0.05), which indicates that the content of any one protein of IGHG2, SERPINA1 and MYO5A in the urine of the patient showed a significant statistically increased change with the progress of diabetic nephropathy.
Examples: urine samples of patients with diabetic nephropathy (men, clinical patients aged over 50 years) of the clinical diabetic department are continuously collected, and urine samples of patients are continuously collected for a plurality of days (or a plurality of periods) respectively. And the content of any one of the three proteins in urine is characterized by performing immunoblotting detection (western-blot detection) by using specific antibodies (high-specificity antibodies of abcam company, IGHG2 antibody No. ab109489, SERPINA1 No. ab207303, MYO5A antibody No. ab 244249) of IGHG2, SERPINA1 and/or MYO5A or using a quantitative detection technology based on mass spectrum. By comparing the content change of any protein of the three proteins in urine of a patient along with the growth of the patient in the disease time, monitoring the trend of the protein expression quantity along with the change of the disease time, drawing a correlation linear curve, and when the content of the protein shows a gradually-increasing linear trend along with the growth of the patient in the disease time (the linear correlation is more than 0.5), the diabetic nephropathy is gradually worsened.
Claims (7)
1. A kit for use in the monitoring of the course of diabetic nephropathy comprising reagents for detecting the expression levels of the biomarkers IGHG2, SERPINA1 and/or MYO5A in a sample.
2. The kit of claim 1, wherein the sample is urine.
3. The kit of claim 1, wherein the reagents are specific antibodies to IGHG2, SERPINA1 and MYO5A, respectively.
4. The kit of claim 1, wherein the kit further comprises instructions for use.
5. Use of an agent that detects the expression level of a biomarker in the manufacture of a product for monitoring the progression of diabetic nephropathy, wherein the biomarker is one or more selected from IGHG2, SERPINA1 and MYO 5A.
6. The use according to claim 5, wherein the product is a detection kit.
7. The use of claim 6, wherein the detection kit further comprises instructions for use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211664448.4A CN118243930A (en) | 2022-12-23 | 2022-12-23 | Kit for monitoring diabetic nephropathy disease course and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211664448.4A CN118243930A (en) | 2022-12-23 | 2022-12-23 | Kit for monitoring diabetic nephropathy disease course and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118243930A true CN118243930A (en) | 2024-06-25 |
Family
ID=91559161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211664448.4A Pending CN118243930A (en) | 2022-12-23 | 2022-12-23 | Kit for monitoring diabetic nephropathy disease course and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118243930A (en) |
-
2022
- 2022-12-23 CN CN202211664448.4A patent/CN118243930A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | Urinary biomarkers in the early diagnosis of acute kidney injury | |
| Schlatzer et al. | Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes | |
| JP4516124B2 (en) | Diagnosis method of liver fibrosis | |
| US20140303021A1 (en) | Methods and devices for detecting obstructive uropathy and associated disorders | |
| EP2664922A1 (en) | Method for prediction of prognosis of sepsis | |
| EP2924439B1 (en) | Ltbp2 as a biomarker for predicting or prognosticating mortality | |
| Kubo et al. | Biological variation of procalcitonin levels in hemodialysis patients | |
| CN111602057A (en) | Workflow for risk assessment and patient management using procalcitonin and mesogenic adrenomedullin | |
| CN112201318A (en) | Application method of laboratory index model in risk stratification of COVID-19 patients | |
| KR102170826B1 (en) | Biomarker for diagnosis or predicting prognosis of stroke and use thereof | |
| CN111477268B (en) | Method for establishing glycoprotein N-glycoset graph spectrum model and application | |
| CN118243930A (en) | Kit for monitoring diabetic nephropathy disease course and application thereof | |
| Vijayaraghavan et al. | Determination of serum glycated albumin and high sensitivity C-reactive protein in the insight of cardiovascular complications in diabetic chronic kidney disease patients | |
| Higby et al. | A comparison between two screening methods for detection of microproteinuria | |
| CN108291903B (en) | Marker for determining diabetic nephropathy | |
| CN108088987A (en) | Application and method for screening high risk of diabetic nephropathy by urine biomarkers | |
| EP2581745B1 (en) | Composition for diagnosis of lung cancer and diagnosis kit of lung cancer | |
| JP2018179669A (en) | Diagnostic marker of diabetic nephropathy | |
| CN118275663A (en) | Kit for monitoring diabetic nephropathy disease course and application thereof | |
| Zhou et al. | A meta-analysis of serum Hcy in diagnosis of diabetic nephropathy | |
| CN117686719B (en) | Early diagnosis marker for diabetic nephropathy, detection kit and application thereof | |
| CN114509573B (en) | Diabetes kidney disease early warning model established based on synchronous detection of urine markers | |
| Khalid et al. | Assessment of Serum Podocalyxin as a Biomarker for Diabetic Nephropathy in Type 2 Diabetes patients in Duhok City | |
| CN115479934B (en) | Aortic dissection combined prognosis evaluation system based on markers and imaging | |
| KR102596890B1 (en) | A Biomarker for Diagnosing Diabetic Nephropathy Comprising Urinary Glycated Albumin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication |